Annual Total Long Term Liabilities
$1.56 B
+$23.59 M+1.53%
December 31, 2024
Summary
- As of February 24, 2025, HALO annual total long term liabilities is $1.56 billion, with the most recent change of +$23.59 million (+1.53%) on December 31, 2024.
- During the last 3 years, HALO annual total long term liabilities has risen by +$770.23 million (+97.46%).
- HALO annual total long term liabilities is now at all-time high.
Performance
HALO Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Long Term Liabilities
$1.56 B
+$4.04 M+0.26%
December 31, 2024
Summary
- As of February 24, 2025, HALO quarterly total long term liabilities is $1.56 billion, with the most recent change of +$4.04 million (+0.26%) on December 31, 2024.
- Over the past year, HALO quarterly long term liabilities has stayed the same.
- HALO quarterly long term liabilities is now -5.89% below its all-time high of $1.66 billion, reached on September 30, 2022.
Performance
HALO Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Long Term Liabilities Formula
Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities
HALO Long Term Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +1.5% | 0.0% |
| 3 y3 years | +97.5% | +2.1% |
| 5 y5 years | +301.7% | +2.1% |
HALO Long Term Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +97.5% | -5.9% | +97.5% |
| 5 y | 5-year | at high | >+9999.0% | -5.9% | >+9999.0% |
| alltime | all time | at high | -100.0% | -5.9% | -100.0% |
Halozyme Therapeutics Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $1.56 B(+1.5%) | $1.56 B(+0.3%) |
| Sep 2024 | - | $1.56 B(+0.6%) |
| Jun 2024 | - | $1.55 B(+1.0%) |
| Mar 2024 | - | $1.53 B(-0.3%) |
| Dec 2023 | $1.54 B(-0.3%) | $1.54 B(+0.6%) |
| Sep 2023 | - | $1.53 B(-1.0%) |
| Jun 2023 | - | $1.54 B(+0.1%) |
| Mar 2023 | - | $1.54 B(+0.0%) |
| Dec 2022 | $1.54 B(+95.0%) | $1.54 B(-7.1%) |
| Sep 2022 | - | $1.66 B(+28.7%) |
| Jun 2022 | - | $1.29 B(+63.1%) |
| Mar 2022 | - | $790.30 M(-0.0%) |
| Dec 2021 | $790.33 M(>+9900.0%) | $790.33 M(-0.0%) |
| Sep 2021 | - | $790.59 M(-0.2%) |
| Jun 2021 | - | $791.86 M(+0.0%) |
| Mar 2021 | - | $791.57 M(>+9900.0%) |
| Dec 2020 | $7.49 M(-98.1%) | $7.49 M(-98.1%) |
| Sep 2020 | - | $398.06 M(+0.7%) |
| Jun 2020 | - | $395.35 M(+0.8%) |
| Mar 2020 | - | $392.31 M(+1.0%) |
| Dec 2019 | $388.47 M(+824.9%) | $388.47 M(+2190.2%) |
| Sep 2019 | - | $16.96 M(-24.1%) |
| Jun 2019 | - | $22.36 M(-26.4%) |
| Mar 2019 | - | $30.40 M(-27.6%) |
| Dec 2018 | $42.00 M(-76.7%) | $42.00 M(-36.0%) |
| Sep 2018 | - | $65.65 M(-24.9%) |
| Jun 2018 | - | $87.40 M(-21.4%) |
| Mar 2018 | - | $111.18 M(-38.3%) |
| Dec 2017 | $180.25 M(-24.7%) | $180.25 M(-1.3%) |
| Sep 2017 | - | $182.71 M(-10.4%) |
| Jun 2017 | - | $204.01 M(-8.7%) |
| Mar 2017 | - | $223.56 M(-6.6%) |
| Dec 2016 | $239.41 M(+213.6%) | $239.41 M(-1.0%) |
| Sep 2016 | - | $241.83 M(-2.2%) |
| Jun 2016 | - | $247.32 M(+14.8%) |
| Mar 2016 | - | $215.40 M(+182.2%) |
| Dec 2015 | $76.33 M(-23.9%) | $76.33 M(-7.0%) |
| Sep 2015 | - | $82.08 M(-7.5%) |
| Jun 2015 | - | $88.78 M(-6.9%) |
| Mar 2015 | - | $95.37 M(-4.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2014 | $100.29 M(+3.5%) | $100.29 M(+11.3%) |
| Sep 2014 | - | $90.09 M(-5.2%) |
| Jun 2014 | - | $95.03 M(+0.5%) |
| Mar 2014 | - | $94.58 M(-2.4%) |
| Dec 2013 | $96.88 M(+44.8%) | $96.88 M(+30.9%) |
| Sep 2013 | - | $74.01 M(+16.7%) |
| Jun 2013 | - | $63.41 M(-3.1%) |
| Mar 2013 | - | $65.43 M(-2.2%) |
| Dec 2012 | $66.93 M(+78.2%) | $66.93 M(+87.2%) |
| Sep 2012 | - | $35.75 M(-1.7%) |
| Jun 2012 | - | $36.37 M(-1.7%) |
| Mar 2012 | - | $36.98 M(-1.5%) |
| Dec 2011 | $37.56 M(-32.5%) | $37.56 M(+0.4%) |
| Sep 2011 | - | $37.40 M(-1.4%) |
| Jun 2011 | - | $37.91 M(-30.8%) |
| Mar 2011 | - | $54.81 M(-1.5%) |
| Dec 2010 | $55.65 M(-0.4%) | $55.65 M(+3.8%) |
| Sep 2010 | - | $53.61 M(-1.7%) |
| Jun 2010 | - | $54.54 M(-0.1%) |
| Mar 2010 | - | $54.59 M(-2.2%) |
| Dec 2009 | $55.85 M(+18.9%) | $55.85 M(+4.0%) |
| Sep 2009 | - | $53.70 M(-1.8%) |
| Jun 2009 | - | $54.69 M(+5.8%) |
| Mar 2009 | - | $51.67 M(+10.0%) |
| Dec 2008 | $46.96 M(+27.5%) | $46.96 M(+21.0%) |
| Sep 2008 | - | $38.80 M(-1.7%) |
| Jun 2008 | - | $39.49 M(-1.3%) |
| Mar 2008 | - | $40.00 M(+8.6%) |
| Dec 2007 | $36.83 M(+96.3%) | $36.83 M(+0.0%) |
| Sep 2007 | - | $36.82 M(+34.5%) |
| Jun 2007 | - | $27.37 M(-1.6%) |
| Mar 2007 | - | $27.81 M(+48.2%) |
| Dec 2006 | $18.76 M(>+9900.0%) | $18.76 M(>+9900.0%) |
| Mar 2004 | - | $0.00(0.0%) |
| Sep 2003 | - | $0.00(0.0%) |
| Jun 2003 | - | $0.00(0.0%) |
| Mar 2003 | - | $0.00(0.0%) |
| Sep 2002 | - | $0.00(0.0%) |
| Jun 2002 | - | $0.00(0.0%) |
| Mar 2002 | - | $0.00 |
| Dec 2001 | $0.00 | - |
FAQ
- What is Halozyme Therapeutics annual total long term liabilities?
- What is the all time high annual total long term liabilities for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual total long term liabilities year-on-year change?
- What is Halozyme Therapeutics quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly long term liabilities year-on-year change?
What is Halozyme Therapeutics annual total long term liabilities?
The current annual total long term liabilities of HALO is $1.56 B
What is the all time high annual total long term liabilities for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual total long term liabilities is $1.56 B
What is Halozyme Therapeutics annual total long term liabilities year-on-year change?
Over the past year, HALO annual total long term liabilities has changed by +$23.59 M (+1.53%)
What is Halozyme Therapeutics quarterly total long term liabilities?
The current quarterly long term liabilities of HALO is $1.56 B
What is the all time high quarterly long term liabilities for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly total long term liabilities is $1.66 B
What is Halozyme Therapeutics quarterly long term liabilities year-on-year change?
Over the past year, HALO quarterly total long term liabilities has changed by $0.00 (0.00%)